HMGB1 and colorectal cancer: Anticancer drugs that increase the release of the high-mobility group box 1 protein (HMGB1) trigger ERK1/2-mediated DRP1 phosphorylation in colorectal cancers, or increased ROS production and hypoxia in ovarian tumors, and are usually associated with fission-driven chemoresistance [470].